oa Diagnostic and Therapeutic Considerations in Concurrent Plasma Cell Dyscrasia and Amyloidosis

References

1. Mankad AK, Sesay I, Shah KB. Light-chain cardiac amyloidosis. Curr Probl Cancer. 2017; 41:(2):144–156.
   [Google Scholar]
2. Sidiqi MH, Dasari S, McPhail ED, et al. Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. Am J Hematol. 2019; 94:5:E141–E143.
   [Google Scholar]
3. Velayutham R, Parale C, Sukumaran SK, Anantharaj A. Cardiac Amyloid as a presenting feature of multiple Myeloma. QJM. 2022.
   [Google Scholar]
4. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology. 2014; 15:12:e538–e548.
   [Google Scholar]
5. Kourelis TV, Kumar SK, Gertz MA, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol. 2013; 31:(34):4319–4324.
   [Google Scholar]
6. Bianchi G, Kumar S. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases. Hematol Oncol Clin North Am. 2020; 34:6:1009–1026.
   [Google Scholar]
7. Schonland SO, Hegenbart U, Bochtler T, et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood. 2012; 119:2:488–493.
   [Google Scholar]
8. National Comprehensive Cancer Network. Systemic Light Chain Amyloidosis (Version 1.2022). https://www.nccn.org/professionals/physician_gls/pdf/amyloidosis.pdf. Accessed July 2. 2022.
9. Kastritis E, Dialoupi I, Gavriatopoulou M, et al. Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. Blood Adv. 2019; 3:20:3002–3009.
   [Google Scholar]
10. Maurer MS, Schwartz JH, Gundapaneni B, et al.. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018 Sep 13; 379:(11):1007–1016.
    [Google Scholar]
11. Kastritis E, Palladini G,Minnema MC et al.. N Engl J Med. 2021 Jul 1; 385:(1):46–58. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
    [Google Scholar]